Evidence map›Paper›PMID 37250910›Full record

ArticleClinical, cosmetic and investigational dermatology2023

Skin Manifestations Among Patients Admitted with COVID-19: A Cross-Sectional Study at a University-Based Tertiary Hospital in Jordan.

Diala M Alshiyab, Firas A Al-Qarqaz, Enas Alhaje, Jihane A Mayou, Saja Jaradat, Ansam Asaad, Jihan M Muhaidat, Yousef Khader, Safa' M Alsheyab, Ashraf O Oweis and 4 more

Open access · goldAbstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Urticaria and mimickers of urticaria.Frontiers in allergy · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Diala M AlshiyabDepartment of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0003-0244-0221
Firas A Al-QarqazDepartment of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0003-4876-7406
Enas AlhajeDepartment of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0003-0039-687X
Jihane A MayouDepartment of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Saja JaradatDepartment of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0009-0001-2856-4866
Ansam AsaadDepartment of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0009-0003-1800-9265
Jihan M MuhaidatDepartment of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-0365-6940
Yousef KhaderDepartment of Public Health, Community Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-7830-6857
Safa' M AlsheyabDepartment of Mathematics and Statistics, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0009-0005-8886-5133
Ashraf O OweisDepartment of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-7581-2025
Basheer Y KhassawnehDepartment of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0003-2160-4498
Suleiman M MomanyDepartment of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-2451-9507
Shaher M SamrahDepartment of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-8811-3741
Musa Al-AliDepartment of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Jordan University of Science and Technology · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COVID-19 pandemic hit the entire world with severe health and economic consequences. Although the infection primarily affected the respiratory system, it was soon recognized that COVID-19 has a multi-systemic component with various manifestations including cutaneous involvement. Objective: The main objective of this study is to assess the incidence and patterns of cutaneous manifestations among moderate-to-severe COVID-19 patients who required hospitalization and whether there was a prognostic indication for cutaneous involvement and the outcome in terms of recovery or death. Methods: This is a cross-sectional observational study that included inpatients who were diagnosed with a moderate or severe COVID-19 infection. The demographic and clinical data of patients were assessed including age, sex, smoking, and comorbidities. All patients were examined clinically for the presence of skin manifestations. Patients were followed for the outcome of COVID-19 infection. Results: A total of 821 patients (356 females and 465 males) aged 4-95 years were included. More than half of patients (54.6%) aged >60 years. A total of 678 patients (82.6%) had at least one comorbid condition, mostly hypertension and diabetes mellitus. Sixty-two patients (7.55%) developed rashes; 5.24% cutaneous and 2.31% oral. The rashes were then grouped into five major types: group A, Exanthema: morbilliform, papulovesicular, varicella-like. Group B, Vascular: Chilblain-like lesions, purpuric/petechial, livedoid lesions. Group C, Reactive erythemas: Urticaria, Erythema multiforme. Group D, other skin rashes including flare-up of pre-existing disease, and O for oral involvement. Most patients (70%) developed rash after admission. The most frequent skin rashes were reactive erythema (23.3%), followed by vascular (20.9%), exanthema (16.3%), and other rashes with flare-ups of pre-existing diseases (39.5%). Smoking and loss of taste were associated with the appearance of various skin rashes. However, no prognostic implications were found between cutaneous manifestations and outcome. Conclusion: COVID-19 infection may present with various skin manifestations including worsening of pre-existing skin diseases.

Indexed as

COVID-19cutaneous manifestationspigmented purpuric dermatosisvitiligo-like hypopigmentation

Identifiers

PMID37250910
PMCPMC10225128
OpenAlexW4378071912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.